Literature DB >> 17563396

Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.

Dirk Kienle1, Tiemo Katzenberger, German Ott, Doreen Saupe, Axel Benner, Holger Kohlhammer, Thomas F E Barth, Sylvia Höller, Jörg Kalla, Andreas Rosenwald, Hans Konrad Müller-Hermelink, Peter Möller, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer.   

Abstract

PURPOSE: There is evidence for a direct role of quantitative gene expression deregulation in mantle-cell lymphoma (MCL) pathogenesis. Our aim was to investigate gene expression associations with other pathogenic factors and the significance of gene expression in a multivariate survival analysis. PATIENTS AND METHODS: Quantitative expression of 20 genes of potential relevance for MCL prognosis and pathogenesis were analyzed using real-time reverse transcriptase polymerase chain reaction and correlated with clinical and genetic factors, tumor morphology, and Ki-67 index in 65 MCL samples.
RESULTS: Genomic losses at the loci of TP53, RB1, and P16 were associated with reduced transcript levels of the respective genes, indicating a gene-dosage effect as the pathomechanism. Analysis of gene expression correlations between the candidate genes revealed a separation into two clusters, one dominated by proliferation activators, another by proliferation inhibitors and regulators of apoptosis. Whereas only weak associations were identified between gene expression and clinical parameters or blastoid morphology, several genes were correlated closely with the Ki-67 index, including the short CCND1 variant (positive correlation) and RB1, ATM, P27, and BMI (negative correlation). In multivariate survival analysis, expression levels of MYC, MDM2, EZH2, and CCND1 were the strongest prognostic factors independently of tumor proliferation and clinical factors.
CONCLUSION: These results indicate a pathogenic contribution of several gene transcript levels to the biology and clinical course of MCL. Genes can be differentiated into factors contributing to proliferation deregulation, either by enhancement or loss of inhibition, and proliferation-independent factors potentially contributing to MCL pathogenesis by apoptosis impairment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563396     DOI: 10.1200/JCO.2006.08.7999

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

Authors:  Katrin Tiemann; Jessica V Alluin; Anja Honegger; Pritsana Chomchan; Shikha Gaur; Yen Yun; Stephen J Forman; John J Rossi; Robert W Chen
Journal:  Leuk Lymphoma       Date:  2011-07-12

Review 2.  Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

Authors:  Brad S Kahl
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Authors:  Warren Fiskus; Rekha Rao; Ramesh Balusu; Siddhartha Ganguly; Jianguo Tao; Eduardo Sotomayor; Uma Mudunuru; Jacqueline E Smith; Stacey L Hembruff; Peter Atadja; Victor E Marquez; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

4.  New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Authors:  David W Scott; Pau Abrisqueta; George W Wright; Graham W Slack; Anja Mottok; Diego Villa; Pedro Jares; Hilka Rauert-Wunderlich; Cristina Royo; Guillem Clot; Magda Pinyol; Merrill Boyle; Fong Chun Chan; Rita M Braziel; Wing C Chan; Dennis D Weisenburger; James R Cook; Timothy C Greiner; Kai Fu; German Ott; Jan Delabie; Erlend B Smeland; Harald Holte; Elaine S Jaffe; Christian Steidl; Joseph M Connors; Randy D Gascoyne; Andreas Rosenwald; Louis M Staudt; Elias Campo; Lisa M Rimsza
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

5.  ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

6.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

7.  Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Authors:  Matthew J Oberley; Saurabh A Rajguru; Chong Zhang; Kyungmann Kim; Gene R Shaw; Kreg M Grindle; Brad S Kahl; Craig Kanugh; Jennifer Laffin; David T Yang
Journal:  Histopathology       Date:  2013-08-08       Impact factor: 5.087

8.  microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics.

Authors:  Alba Navarro; Guillem Clot; Miriam Prieto; Cristina Royo; Maria Carmela Vegliante; Virginia Amador; Elena Hartmann; Itziar Salaverria; Sílvia Beà; Jose Ignacio Martín-Subero; Andreas Rosenwald; German Ott; Adrian Wiestner; Wyndham H Wilson; Elías Campo; Luis Hernández
Journal:  Clin Cancer Res       Date:  2013-05-02       Impact factor: 12.531

9.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

Authors:  Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said
Journal:  Leuk Lymphoma       Date:  2008-11

Review 10.  Research progress on epigenetics of small B-cell lymphoma.

Authors:  Xueqin Ruan; Rong Zhang; Hongkai Zhu; Can Ye; Zhihua Wang; En Dong; Ruijuan Li; Zhao Cheng; Hongling Peng
Journal:  Clin Transl Oncol       Date:  2022-03-25       Impact factor: 3.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.